Clinical reviewer: Dr. Sarah Boss, MD

COGNIFUL, part of THE BALANCE GROUP, publishes this comparison. We discuss selected clinical routes alongside our own residential program, with no claim to an independent ranking. Private and luxury describe preferences about access and setting. They do not establish withdrawal expertise, the correct diagnosis or whether a person should leave their existing care team. [1]

A GP may know about one prescription while a private specialist or another service holds information about others. A person may also use nonprescription products or medication obtained outside the original plan. Before selecting treatment, ask a responsible clinician to reconcile the complete list. Include exact formulations, actual use, recent changes and the reason each medicine was started.

Physical dependence is not the same as addiction. Benzodiazepine dependence can develop during prescribed use without impaired control or other features of a substance use disorder. Conversely, a legitimate original prescription does not prevent a harmful pattern from developing later. The clinical review should determine which problem is present rather than rely on the word prescription as reassurance or the word dependence as a diagnosis of addiction. [2]

The NHS describes a GP or local drug treatment service as potential entry points for help, with private services also available. For someone concerned specifically about prescribed sedatives, ask the local clinician which service actually manages that situation. A general drug-service directory does not prove that every service accepts every medication-withdrawal case. [3]

Priory Hospital Roehampton describes medically assisted detox, inpatient addiction treatment and outpatient options in London. Ask which program would apply to the precise prescription history rather than assuming every service has the same admission criteria. A local GP or specialist route may provide stronger continuity when the main need is a gradual medication review rather than a residential addiction program. [4]

Mallorca is an additional residential option for suitable needs, not a substitute address for a UK medical team. The practical comparison should include how records move, who remains responsible for prescriptions and whether follow-up appointments have been accepted at home. A return flight is not a clinical handover. These arrangements deserve attention before a family pays for a stay abroad.

Dependence during prescribed use

If the medicine has been taken as instructed but stopping feels difficult, ask for a review that recognizes dependence without presuming misuse. With benzodiazepines, abrupt stopping or reducing too quickly can cause serious withdrawal, including seizures. Do not stop medication in order to arrive at a program medication-free. The responsible clinician should determine how any change is approached and which setting is needed. [6]

Use that has become difficult to control

When the pattern includes repeated extra doses, concealment, obtaining multiple supplies or continued use despite harm, addiction assessment may be needed. Treatment should explore the function of the medicine in daily life: relief of pain, avoidance of distress, sleep, performance or another purpose. Psychological work is more useful when it addresses that function and the consequences of use rather than treating the medication list as the whole problem.

Opioid-related concerns

For opioid pain medication, preserve a plan for pain while assessing possible opioid use disorder. The CDC recommends medication treatment for that disorder and advises against detoxification alone because of increased return-to-use and overdose risk. Ask any proposed program how appropriate opioid treatment is provided or arranged and how it connects with care in the UK after discharge. [7]

Sleep and anxiety needs

The original anxiety or insomnia should remain visible when a sedative is reviewed. A person may fear that discussing dependence will mean losing all help for the condition that led to treatment. Ask what alternative or continuing care is proposed. For chronic insomnia, evidence-based sleep treatment such as CBT-I should be considered by an appropriate professional; availability at a particular residence must be confirmed. [8]

Local treatment can be especially practical when a stable person needs extended prescribing review, familiar clinicians or frequent appointments near home. It may also allow therapy to address the situations where difficulties actually occur. A private hospital can be considered when the assessed medical or psychiatric needs require that level of care. These are clinical choices, not conclusions based on whether someone can afford overseas treatment.

If current symptoms suggest severe withdrawal, overdose or another emergency, use urgent local medical services. Traveling to a preferred residence should not delay assessment. Tell the reviewing professional about previous seizures, complicated withdrawal, other sedatives and relevant medical conditions. An outwardly organized or high-functioning life does not remove those risks. [6]

For some people, a period away from work and familiar pressures may create room for sustained therapeutic work. Ask what specifically requires residential care and how the benefits will carry back into UK life. If the answer depends only on distance, it may not yet explain how the program addresses the prescription problem or how the person will manage after returning.

COGNIFUL’s actual location is Mallorca. Its published prescription-medication service emphasizes assessment, the distinction between dependence and addiction, and the difference between withdrawal care and residential rehabilitation. Admission requires clinical suitability and availability. A UK resident should expect the review to consider current medication, medical stability, previous treatment and the practical arrangements for continuing care across the transition. [1]

The residence takes a maximum of four clients at any time, with a private suite for each. Individual clinical and bodywork sessions sit within shared residential life: the chef, personal manager, common setting, other holistic sessions, excursions and activities are shared. This can be evaluated as a living and treatment format. It does not promise an exclusive property, dedicated one-client staffing or a fixed amount of therapy. [5]

Ask how your particular prescription concern would be addressed during the stay. If the work involves anxiety, relationships, coping or a harmful pattern of obtaining medication, request an explanation of the proposed goals and clinical input. If it requires specialist pain treatment, a particular sleep intervention or medical withdrawal care, confirm the responsible service rather than infer it from the general treatment description. [9]

COGNIFUL Premier and Premier Plus both include assessment, an individual treatment plan and continuing-care planning; Plus adds individual therapeutic work, family and transition work, and three months of aftercare. Base-program follow-up is agreed individually. A typical stay is four to twelve weeks, reviewed individually, and should not be interpreted as a promised duration for medication withdrawal. [5] View program fees

The proposal should clarify total fees, duration, inclusions and additional costs in euros. COGNIFUL is generally self-pay and does not bill insurers directly; reimbursement is not guaranteed. For a UK payer, also budget for actual travel and any external clinical arrangements without assuming they are included. Compare the programs by the work and follow-up proposed, not by a claim that the higher price automatically produces better recovery.

Before leaving the UK, confirm the prescribing arrangement during the stay and the clinician who has agreed to resume or continue care afterward. The return-home plan should include appointments and a medication summary understandable to the UK team. COGNIFUL’s continuing-care planning can address this transition, but the individual agreement determines follow-up. Do not assume the aftercare offer includes unrestricted cross-border prescribing or every form of remote clinical treatment. [10]

Ask the receiving UK clinician whether they have the information needed and whether the first appointment is booked. If several services were involved before admission, decide who now holds the overall plan. A letter sent to a practice is not proof that a particular specialist has accepted an ongoing prescription or therapy responsibility.

Discuss the situations that may become difficult again: a return to demanding work, disrupted sleep, pain flares, easy access to additional supplies, or family pressure to be fully recovered. The plan should specify whom to contact and how concerns are reviewed. Relatives can support the person without independently controlling medication changes. Clinical responsibility should remain with the appropriate professionals.

• What does the assessment conclude about dependence, addiction and the original condition?
• Why is this level of care recommended, and what could be managed locally?
• Who is responsible for prescribing before, during and after a stay abroad?
• What does the proposed family work address, and what information can be shared with consent?
• Which follow-up appointments are confirmed, which are only recommended, and what costs remain separate?

Keep these answers alongside the quoted price. If a program has not resolved a prescribing gap, additional amenities do not resolve it. If local outpatient care is sufficient, the absence of a residential recommendation should be seen as useful clinical guidance. The aim is a suitable treatment route that remains workable after the initial decision.

Can my GP be involved if I choose private treatment?

Coordination can be discussed with your consent, but each clinician’s role must be agreed. Do not assume a GP will automatically take over a prescription or plan made elsewhere. Ask the proposed provider to clarify the handover and obtain acceptance from the relevant UK professional. [9]

Does benzodiazepine dependence require addiction rehab?

Not necessarily. Dependence may develop with prescribed use and can require medication review without a substance use disorder. Other people need addiction treatment or a higher medical level of care. Assessment determines the distinction and the appropriate setting. [2]

Is COGNIFUL a UK clinic?

No. COGNIFUL’s residence is in Mallorca, Spain. UK residents can inquire about suitability, but travel, medical responsibilities and return-home care need to be planned around that actual location. [5]

Can I stop my tablets before traveling?

Do not change them independently to prepare for treatment. In particular, abrupt benzodiazepine withdrawal can be dangerous. Discuss the actual medication and travel timing with the responsible clinician before making changes. [6]

Contact COGNIFUL admissions to explore whether a Mallorca residential stay fits the assessed prescription-medication needs. Explain your existing UK care, the actual medicines involved and any withdrawal history. A clear next step should identify the appropriate medical pathway as well as the possible residential work. [5]

1. Prescription medication concerns and residential treatment — COGNIFUL.
2. Joint Clinical Practice Guideline on Benzodiazepine Tapering — American Society of Addiction Medicine and partner societies.
3. Drug addiction: getting help — NHS.
4. Priory Hospital Roehampton — Priory.
5. COGNIFUL programs, fees, admissions and suitability — COGNIFUL.
6. Benzodiazepine safety communication — US Food and Drug Administration.
7. Opioid use disorder: treating — Centers for Disease Control and Prevention.
8. Insomnia treatment — National Heart, Lung, and Blood Institute.
9. Clinical scope, suitability and care coordination — COGNIFUL.
10. Reintegration and continuing care — COGNIFUL.

Primary clinical and provider pages accessed October 18, 2026. Individual services, admission and fees should be confirmed directly.